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We read with interest the article by Dai and Col-
leagues [1] evaluating the association of virologic sta-
tus with serum lipids in hepatitis C virus (HCV)
antibody positive subjects. In their study carried out
in 11,239 residents in an area endemic for both hepa-
titis B virus (HBV) and HCV infection, the authors
observed that HCV viraemia seems to be associated
with both low serum total cholesterol and triglyceride
levels. Furthermore, they observed that anti-HCV sub-
jects who were positive for HCV-RNA were more
likely to be aﬀected by diabetes as compared to
HCV-RNA negative ones (odds ratio = 3.592). On
the basis of their results they conclude that HCV itself
might play a signiﬁcant role on serum lipid proﬁles in
these patients.
Although we agree with the authors that, as re-
cently reviewed, the biology of HCV is strictly entan-
gled with lipid homeostasis [2,3], we also
acknowledge the fact that other aspects not taken
into account by the authors may be responsible for
low lipid serum levels in patients with supposed liver
disease. Indeed, it has been clearly shown that a sta-
tistically signiﬁcant trend towards lower serum choles-
terol levels exists among patients with cirrhosis,
chronic hepatitis and controls [4], that low serum
cholesterol levels are independently associated with
signiﬁcant ﬁbrosis in HCV patients [5,6], and that a
progressive decrease in serum cholesterol has prog-
nostic value in patients with decompensated viral cir-
rhosis [7]. Thus, what is missing in the study by Dai
and colleagues is the clinical status of their HCV
subjects, and whether patients who were HCV-RNA
negative were spontaneously so, or the condition
had been induced by previous anti-viral therapy. Fur-
thermore, since in the study population HBV surface
antigen positivity was independently associated with
low serum lipid levels as well it is not clear why
HBV-DNA status of the patients was not investi-
gated. Thus, it is reasonable to hypothesise that the
non-viraemic anti-HCV population included in the
study was made up of ‘‘subjects”, while HCV-RNA
positive subjects were actually patients. This hypothe-
sis is emphasised by the fact that patients without ele-
vated cholesterol levels were signiﬁcantly more likely
to have abnormal alanine aminotransferase, a coun-
terintuitive phenomenon in an era of positive associa-
tion between altered liver enzymes, dyslipidemia, and
liver steatosis [8]. Finally, the independent association
between diabetes and HCV-RNA positivity in the
study population further strengthens this hypothesis,
since patients with (advanced) liver disease – not only
those infected by HCV – are more likely to be af-
fected by diabetes [9]. Therefore, the hypotheses put
forward by the authors regarding the association be-
tween serum lipids and HCV-RNA status in their
population, albeit conceivable and interesting, remain
largely speculative and the observed association
rather spurious in the absence of deeper insights into
the clinical and virologic characterisation of their
population.
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Hepatitis C viremia and serum lipid levels: A clue from
an epidemiology study
To the Editor:
We would like to thank Dr. Giannini and Dr. Sava-
rino for their interest in our article and we appreciate
their comments. The clinical status of hepatitis C virus
(HCV) infection in terms of the severity of histopathol-
ogy is lacking in our study [1]. It is indeed neither
appropriate nor possible to undergo liver biopsy for
more than 11,000 residents in a large-scale study.
Based on the cross-sectional survey in our commu-
nity-based study, we found HCV-viremic patients had
lower serum lipid levels than anti-HCV-negative or
anti-HCV-positive (but non-viremic) individuals which
provided strong evidence of the association between
HCV viremia and lower serum lipid levels. Further-
more, with the advantage of a large scale study, our re-
port demonstrated the impact of HCV viremia among
anti-HCV positive individuals. We also observed hepa-
titis B virus surface antigen positivity was indepen-
dently associated with low serum lipid levels by
multivariate analysis. The residents enrolled were aged
40–65 years and around 10% of them, according to
previous studies, may be positive for hepatitis B e anti-
gen which has been recognized to be strongly associ-
ated with an increased risk of active cirrhosis [2,3]. In
addition, we have also observed a reciprocal viral inter-
action between hepatitis B virus (HBV) and HCV after
interferon-alpha/ribavirin therapy [4]. Hence, HBV
infection might play a less important role among
anti-HCV-positive subjects, particularly among the
HCV viremic patients in our study. Nevertheless, the
lack of HBV DNA is an important limitation in our
study to validate the association between serum lipid
levels and the severity as well as viral load of chronic
HBV infection.
Recently, the association between cholesterol meta-
bolic pathway and the life cycle in terms of HCV pro-
duction, secretion and entry by human hepatocytes has
been reported [5,6]. HCV replicates on membrane vesi-
cles involved in the assembly and secretion of very
low-density lipoproteins and the low density lipoprotein
receptor involved in HCV entry were observed [7,8].
Incidentally the development of drugs that target the
cholesterol or lipoprotein metabolism and might be use-
ful in treating HCV infection by inhibition of HCV
RNA replication or production of HCV particles from
infected cells is still ongoing, although their safety pro-
ﬁles and beneﬁts require more suﬃcient evidence
[5,9,10]. Accordingly, we believe our epidemiologic
study, also taking the viral genotype into consideration,
implicates an evident association between HCV RNA
status and serum lipids. We deem it necessary at the
same time to investigate the mechanisms of interaction
between HCV and lipids.
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